Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530088 · ClinicalTrials.gov registry record · NA
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
A NA study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00530088 is a NA study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00530088, a NA study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy using porfimer sodium may be effective against mouth or throat dysplasia and cancer of the mouth and throat. PURPOSE: This phase I trial is studying how well photodynamic therapy using porfimer sodium works in treating patients with recurrent mouth or throat dysplasia, recurrent in situ cancer of the mouth or throat, or stage I cancer of the mouth or throat.
Interventions
- DRUG porfimer sodium
- DRUG Photdynamic Therapy (PDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-10 |
| Est. Completion | 2010-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530088
The ClinicalTrials.gov registry entry for NCT00530088 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which porfimer sodium is the first listed.
NCT00530088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530088 about?
NCT00530088 is a clinical study titled "Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat". RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy using porfimer sodium may be effective against mouth or throat dysplasia and cancer of the mouth and throat. PURPOSE: ...
What is the current status of trial NCT00530088?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2001-10. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00530088?
The interventions under investigation include: porfimer sodium (DRUG), Photdynamic Therapy (PDT) (DRUG).
Who is sponsoring clinical trial NCT00530088?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.